RBC Capital maintains Arrowhead Pharma at Outperform, keeps price target at $100
Less than 1 min read
RBC Capital maintained Arrowhead Pharma at Outperform and kept its price target at $100.
The price target implies an upside of 112.1% from the Nov 12 close of $47.15.
Recent analyst actions on Arrowhead Pharma
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 13 | Stifel | Maintains | Buy | $96 |
| Oct 15 | UBS | Assumes | Buy | $109 |
| Oct 15 | Chardan Capital | Maintains | Buy | $115 |
| Oct 15 | HC Wainwright & Co. | Reiterates | Buy | $120 |
Across the four most recent analyst notes published on Arrowhead Pharma over the past 30 days, price targets range from $96 to $120.
Explore more price target data and ratings for Arrowhead Pharma on the Forecasts tab, and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
Read the full article
Get unlimited access to analyst updates and every other article on TradingView.